
We review antifungal susceptibility testing and the development of clinical breakpoints, and detail an approach to using antifungal susceptibility results when breakpoints have not been defined. This information may prove helpful when selecting therapy for invasive fungal infections in children.
epidemiological cutoff value, Antifungal Agents, Humans, broth microdilution, Microbial Sensitivity Tests, minimum inhibitory concentration, clinical breakpoint, Fluconazole, invasive fungal disease, Candida
epidemiological cutoff value, Antifungal Agents, Humans, broth microdilution, Microbial Sensitivity Tests, minimum inhibitory concentration, clinical breakpoint, Fluconazole, invasive fungal disease, Candida
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 12 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
